Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


People In Brief

This article was originally published in The Tan Sheet

Executive Summary

FDA appoints global, IT heads: The agency has chosen Lou Valdez as associate commissioner for international programs and Lori Davis as chief information officer. Valdez will lead the agency's further international expansion, with office openings planned for India, Latin America and the Middle East, FDA says Jan. 12. Melinda Plaisier stepped down as associate commissioner for international programs in October to become director of the Central region office in FDA's Office of Regulatory Affairs (1"The Tan Sheet" Dec. 8, 2008, p. 8). Davis has been deputy CIO since November 2007 and will now drive FDA's multi-year information technology modernization program, which will improve import and food protection by enhancing system interoperability

You may also be interested in...

HBW US Market News: Awards, Appointments, Actions And Nutrition And Disaster Relief

Kochanowski retires with CHPA Career Achievement award; Haelon’s Paley chairs CHPA board; House Oversight Committee chair, FTC commissioner speak at NCPA Fly-In; NasoClenz provided to help consumers following East Palestine disaster; CRN’s Mister attends White House End Hunger launch.

Opening China Offices Brings FDA Early Test On Bridging Globalization Gaps

FDA's opening of offices in China will be an early test of how the agency handles the challenges of globalization, not only in working with foreign governments but also in restructuring itself to operate with worldwide footing

Sales & Earnings In Brief

Schering-Plough looks to emerging markets: As the U.S. economy continues to falter, Schering-Plough is increasingly focusing on emerging markets such as Brazil, China and Russia, CEO Fred Hassan says in an Oct. 21 third-quarter earnings release. He notes 70 percent of S-P's $4.6 billion in third-quarter net sales were outside the U.S. He adds, consumer and animal health account for approximately $758 million and $278 million of sales respectively. Laxative Miralax drove a 2 percent increase in OTC revenues with $31 million in sales - nearly double last year's third-quarter total. This was not enough to offset weak allergy sales with Claritin down 11 percent to $92 million. Other OTC sales slipped 11 percent to $37 million, contributing to a 1 percent fall of overall OTC sales to $160 million. Beyond OTCs, Kenilworth, N.J.-based S-P's net income fell 21 percent to $589 million in the third quarter

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts